News for NiSource Inc. (NOU.F)

In this article, we shared the 11 best natural gas stocks to buy now. You can skip our analysis of the natural gas industry and its growth catalysts and...

The following slide deck was published by NiSource Inc.

Northern Indiana Public Service Co. says 1,625-MW R.M. Schahfer coal plant as part of an accelerating transition to cleaner energy resources

NiSource, Inc. (NYSE:NI) Q4 2020 Earnings Conference Call February 17, 2021 11:00 AM ET Company Participants Randy Hulen - VP, IR & Treasurer Joseph Hamrock - President, CEO &...

/PRNewswire/ -- NiSource Inc. (NYSE: NI) today announced, on a GAAP basis, net income available to common shareholders for the three months ended December 31,...

Tuesday Morning Market Highlights, Stocks: OXY,AKAM,MCD,NI,NOV,LITE,COHR, release date:Jan 19, 2021

Diabetic Peripheral Neuropathy Pipeline Report helps in identifying emerging players in the market and their portfolios. The global Diabetic Peripheral Neuropathy therapeutic landscape evaluates based on mechanism of action (MoA), route of administration (RoA), phases of development, and molecule type.Los Angeles, USA, Jan. 14, 2021 (GLOBE NEWSWIRE) -- Diabetic Peripheral Neuropathy Pipeline Assessment 2020: Therapeutic Analysis Report Featuring 20+ Companies & 15+ Drug Profiles Diabetic Peripheral Neuropathy Pipeline Report helps in identifying emerging players in the market and their portfolios. The global Diabetic Peripheral Neuropathy therapeutic landscape evaluates based on mechanism of action (MoA), route of administration (RoA), phases of development, and molecule type.  “Diabetic Peripheral Neuropathy Pipeline Analysis” by DelveInsight features the details around the Diabetic Peripheral Neuropathy pipeline landscape, unmet needs, and Diabetic Peripheral Neuropathy therapeutic assessment of the key pipeline therapies. Some of the chief Diabetic Peripheral Neuropathy Pipeline Highlights  * 20+ key companies are working to strengthen the Diabetic Peripheral Neuropathy pipeline including the Regenacy Pharmaceuticals LLC, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Pure Green, and several others. * Diabetic Peripheral Neuropathy market presents promising and a vast new product pipeline with pivotal trials, NME Projects and phase-advancing therapeutic candidates. * 15+ Pipeline therapies in different states of clinical development. Pipeline drugs profiled in the report include Ricolinostat, FE-SYHA1402, etc. * Collaborations and Deals * Pipeline Drug Profiles provided include: * Current Status of Development including phase advancements, regulatory approvals of phases, acquisitions, licensing and technology transfers, product launches in various markets, and others. * Phases of development of Diabetic Peripheral Neuropathy Drugs * Mechanism of Action * Route of Administration * Diabetic Peripheral Neuropathy Companies involved including originator, licensing companies, developer, investors, and others * New molecular entity details * Drug designations and other special status provided by regulatory authorities * Diabetic Peripheral Neuropathy Market Drivers and Barriers * Diabetic Peripheral Neuropathy Therapeutics Market LandscapeRequest for Diabetic Peripheral Neuropathy Pipeline Assessment Sample ReportDiabetic Neuropathy is nerve damage caused by diabetes. When it affects the arms, hands, legs, and feet, it is known as Diabetic Peripheral Neuropathy. Diabetic Peripheral Neuropathy pipeline report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical, and discovery. Diabetic Peripheral Neuropathy Emerging Drugs   * FE-SYHA1402 by CSPC ZhongQi Pharmaceutical Technology Co., Ltd.ZhongQi Pharmaceutical Technology is conducting a multiple doses study to assess the safety, tolerability, pharmacokinetics of SYHA1402 in healthy candidates. This study comprises two parts: The objective of the food effect study (Part 1) is to evaluate the effect of food on the pharmacokinetic profiles of SYHA1402 tablets under fed and fasted conditions following the oral administration of SYHA1402. The aim of the multiple doses study (Part 2) is to examine the safety, tolerability, and Pharmacokinetics of SYHA1402 in healthy subjects following oral administration of multiple rising doses. Secondary objectives are the exploration of pharmacokinetics (PK) following multiple oral doses. * VM202 by HelixmithVM202 (donaperminogene seltoplasmid) is a first-in-class, proprietary, non-viral, potentially regenerative plasmid DNA gene therapy. VM202 is a novel genomic cDNA hybrid human hepatocyte growth factor (HGF) gene with a novel and proprietary coding sequence (HGF-X7) expressing two isoforms - a configuration that closely mimics HGF productions in humans that is required for optimal therapeutic benefits. Because there is no change in the coding region of the HGF gene, HGF proteins generated from VM202 are identical to wild-type human HGF proteins. * NYX-2925 by AptinyxNYX-2925 is a novel, oral small molecule NMDA receptor modulator in development for chronic pain treatment. Dysregulation of glutamatergic circuits in the brain is required in the development of centralized chronic pain. NYX-2925 is in late-stage clinical development across two chronic pain indications -Painful Diabetic Peripheral Neuropathy and Fibromyalgia. * LX9211 by Lexicon PharmaceuticalsLX9211 is a potent, orally delivered, selective small-molecule inhibitor of AAK1, a target discovered and extensively characterized in an alliance with Bristol Myers Squibb. Preclinical data displayed central nervous system penetration and lessen in pain behaviour in models of neuropathic pain. Lexicon has exclusive research, development, and commercialization rights to LX9211 and additional compounds acting through AAK1.For further product profiles, request @ Diabetic Peripheral Neuropathy Pipeline Analysis Sample ReportScope of Diabetic Peripheral Neuropathy Drug Pipeline Report  * Coverage: Global  * Major Players: 20+ Key Companies   * Diabetic Peripheral Neuropathy Prominent Players: Regenacy Pharmaceuticals LLC, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Pure Green, Helixmith Co., Ltd., Bayer, Aptinyx, Eliem Therapeutics (UK) Ltd., Lexicon Pharmaceuticals, WinSanTor, Inc, Haisco Pharmaceutical Group Co., Ltd., Eli Lilly and Company, Daiichi Sankyo Co., Ltd., Avazzia, Inc, POLYSAN Scientific & Technological Pharmaceutical Company, Achelios Therapeutics Inc, Applied Therapeutics, Bionevia Pharmaceuticals, Regenacy Pharmaceuticals, Commence Bio Inc, Grunenthal GmbH, Immune Pharmaceuticals, and many others.   * Key Drugs Profiles: 15+ Products   * Diabetic Peripheral Neuropathy Drugs Profiles: Ricolinostat, FE-SYHA1402, CBD, Engensis, BAY1817080, NYX-2925 50, ETX-018810, LX9211, WST-057 (4% pirenzepine), HSK16149, LY3016859, Mirogabalin, Electrical Stimulation, Cytoflavin (Inosine + Nicotinamide + Riboflavin + Succinic Acid), AT 001, BNV-222, Amitriptyline/ketamine, and many others.   * Phases:   * Diabetic Peripheral Neuropathy Therapies Late-stage (Phase III)   * Diabetic Peripheral Neuropathy Therapies (Phase II) * Diabetic Peripheral Neuropathy Therapies (Phase I)  * Diabetic Peripheral Neuropathy Therapies Pre-clinical stage and Discovery candidates  * Discontinued and Inactive candidates  * Molecule Types:   * Small molecule * Gene Therapies  * Route of Administration: * Infusion * Intradermal * Intramuscular * Intranasal * Intravaginal * Oral * Parenteral * Subcutaneous * Topical * Product Types: * Mono * Combination  * Mono/Combination Key Questions regarding Current Diabetic Peripheral Neuropathy Drug Treatment Landscape and Emerging Therapies Answered in the Pipeline Report   * What are the current options for Diabetic Peripheral Neuropathy treatment? * How many companies are developing therapies for the treatment of Diabetic Peripheral Neuropathy?  * How many Diabetic Peripheral Neuropathy emerging therapies are in the early-stage, mid-stage, and late stages of development for the treatment of Diabetic Peripheral Neuropathy? * What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and major licensing activities that will impact the Diabetic Peripheral Neuropathy market?  * Which are the dormant and discontinued products and the reasons for the same? * What is the unmet need for current therapies for the treatment of Diabetic Peripheral Neuropathy?   * What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing Diabetic Peripheral Neuropathy therapies?  * What are the key designations that have been granted for the emerging therapies for Diabetic Peripheral Neuropathy?  * How many patents are granted and pending for the emerging therapies for the treatment of Diabetic Peripheral Neuropathy? Table of Contents 1Introduction 2Executive Summary of Diabetic Peripheral Neuropathy 3Diabetic Peripheral Neuropathy Overview 4Diabetic Peripheral Neuropathy Pipeline Therapeutics 5Diabetic Peripheral Neuropathy Therapeutic Assessment 6Diabetic Peripheral Neuropathy – DelveInsight’s Analytical Perspective 7Diabetic Peripheral Neuropathy Late Stage Products (Phase III) 7.1Engensis: Helixmith Co., Ltd. 8Diabetic Peripheral Neuropathy Mid Stage Products (Phase II) 8.1Aptinyx: NYX-2925  8.2LX9211: Lexicon Pharmaceuticals  9Diabetic Peripheral Neuropathy Early Stage Products (Phase I) 9.1FE-SYHA1402: CSPC ZhongQi Pharmaceutical Technology Co., Ltd. 9.2SR419: SIMR (Australia) Biotech Pty Ltd.  10Diabetic Peripheral Neuropathy Pre-clinical and Discovery Stage Products 11Diabetic Peripheral Neuropathy Inactive Products 12Diabetic Peripheral Neuropathy Comparative Analysis  13Diabetic Peripheral Neuropathy Key Companies 14Diabetic Peripheral Neuropathy Key Products 15Company-University Collaborations (Licensing/Partnering) Analysis 16Diabetic Peripheral Neuropathy Unmet Needs 17Diabetic Peripheral Neuropathy Market Drivers and Barriers 18Diabetic Peripheral Neuropathy- Future Perspectives and Conclusion 19Diabetic Peripheral Neuropathy Analyst Views 20Appendix Browse Detailed TOC, Emerging Drugs and Key Companies @ Diabetic Peripheral Neuropathy Pipeline Analysis ReportRelated Reports  * Diabetic Peripheral Neuropathy Market Analysis DelveInsight's Diabetic Peripheral Neuropathy Market Insights, Epidemiology, and Market Forecast - 2030 report provides an in-depth understanding of historical and forecasted epidemiology. * Diabetic Peripheral Neuropathy Epidemiology Forecast Analysis DelveInsight’s ‘Diabetic Peripheral Neuropathy Epidemiology Forecast-2030’ report delivers an in-depth understanding of the disease, historical, forecasted epidemiology trends of DPN in 7MM.  * Dementia with Diabetes Market Analysis DelveInsight's Dementia with Diabetes Market Insights, Epidemiology, and Market Forecast - 2030 report provides an in-depth understanding of historical and forecasted epidemiology. * Diabetic Foot Market Analysis DelveInsight's Diabetic Foot Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and an in-depth understanding of historical and forecasted epidemiology. * Diabetic Gastroparesis Market Analysis DelveInsight's Diabetic Gastroparesis Market Research Report presents a detailed analysis of the market listing Diabetic Gastroparesis Epidemiology, Drug therapies, market trends in 7MM.  * Diabetic Kidney Disease Market Analysis DelveInsight's Diabetic Kidney Disease (DKD) Market Insights, Epidemiology, and Market Forecast - 2030 report provides a detailed overview of the disease and an in-depth understanding of historical and forecasted epidemiology. * Diabetes Market Analysis  DelveInsight's Diabetes Market Insights, Epidemiology, and Market Forecast - 2030 report provides thorough insights on epidemiology and market trends.About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance.   CONTACT: Contact Us: Shruti Thakur  [email protected]  +1(919)321-6187  www.delveinsight.com

Aurora, IL, Jan. 14, 2021 (GLOBE NEWSWIRE) -- CMC Materials (Nasdaq: CCMP), a leading global supplier of consumable materials to semiconductor manufacturers and pipeline companies, announced the timing of its earnings release and conference call information for the first quarter of fiscal year 2021, which ended December 31, 2020. The earnings release, slide presentation and corresponding prepared remarks will be available in the Investor Relations section of the company’s website, cmcmaterials.com, after market close on Wednesday, February 3, 2021. Conference call: Thursday, February 4, at 10:00 a.m. Eastern Time Dial-in information:   United States: (833) 714-0937                                    International: (778) 560-2685                                    Conference code:  4539453During the live call, the management team will begin with a brief synopsis of the quarter followed by a comprehensive question and answer session. ABOUT CMC MATERIALS, INC.CMC Materials, Inc. (Nasdaq: CCMP) is a global supplier of consumable materials to semiconductor manufacturers and pipeline companies. The company is a leader in developing high-quality, critical materials that enable superior performance for its customers. CMC Materials’ mission is to create value by delivering high-performing and innovative solutions that solve its customers’ greatest challenges. The company’s solutions play a critical role for its customers’ operations, including helping to enable the manufacturing of smaller, faster and more complex semiconductor devices, and enhancing operations and improving manufacturing efficiencies. The company has approximately 2,100 employees globally. For more information, visit www.cmcmaterials.com or contact Colleen Mumford, Vice President, Communications and Marketing, at 630-499-2600. CONTACT: Contact: Colleen Mumford Vice President, Communications and Marketing CMC Materials, Inc. (630) 499-2600

San Jose, CA, Jan. 14, 2021 (GLOBE NEWSWIRE) -- The Santa Clara County Association of REALTORS® (SCCAOR) installed Doug as its President during a virtual ceremony on January 7, 2021. He will serve as the 2021 President of SCCAOR, a real estate trade organization that represents over 6,400 REALTOR® and Affiliate members in Santa Clara County.“I am honored to represent the Santa Clara County Association of REALTORS® this year for their 125th Anniversary,

EDMONTON, Alberta, Jan. 14, 2021 (GLOBE NEWSWIRE) -- Melcor Real Estate Investment Trust (TSX: MR.UN) announces that the REIT’s Board of Trustees met to confirm Q1-2021 distributions and several other matters. Ralph Young, Chair of the Board commented: “I am pleased to report to unitholders, on behalf of the Board, that business conditions, financial results and our outlook for 2021 have precipitated a 17% increase to our distributions for the first quarter of 2021. In addition, we have reviewed and considered other measures that were undertaken in order to preserve cash at the beginning of the COVID pandemic. * The Board approved Q1 distributions of $0.035 per unit for each of the first three months of 2021. This represents a 17% increase over distributions for the previous three quarters. Distribution decisions will be made quarterly based on conditions at that time. The distributions will be payable as follows:MonthRecord DateDistribution DateDistribution Amount January 2021January 29, 2021February 16, 20210.035 per unit February 2021February 26, 2021March 15, 20210.035 per unit March 2021March 31, 2021April 15, 20210.035 per unit * The Board reviewed the reinstatement of the Normal Course Issuer Bid; however, have determined that the decision will have to await the completion of the regularly scheduled year-end trading blackout. The Board will review their decision when the Automatic Share Purchase Plan can be reactivated. * The Board has also formally established an Independent Committee to examine and recommend regular renewals and/or amendments to agreements between Melcor Developments Ltd. and the REIT and other matters as directed by the Board. The Independent Committee will be chaired by independent and Lead Trustee Larry Pollock. The Board of Trustees remains committed to preserving and enhancing value for all Unitholders.Q4/Fiscal Year 2020 Conference Call Earnings Announcement & Conference Call.Melcor REIT also announces that results for Q4/FY-2020 will be released on March 4, 2021 after market close. Management will host a conference call at 11:00 am ET (9:00 am MT) on Friday, March 5, 2021.Toronto & Area: 1-416-915-3239 Toll Free: 1-800-319-4610Webcast & ReplayThe call will also be webcast (listen only) at https://www.gowebcasting.com/11057. A replay of the call will be available at the same URL shortly after the call is concluded.About Melcor REITMelcor REIT is an unincorporated, open-ended real estate investment trust. Melcor REIT owns, acquires, manages and leases quality retail, office and industrial income-generating properties in Western Canada. Its portfolio is currently made up of interests in 39 properties representing approximately 3.21 million square feet of gross leasable area located across Alberta and in Regina, Saskatchewan and Kelowna, British Columbia. For more information, please visit www.melcorREIT.ca.Forward-Looking StatementsThis press release may contain forward‐looking information within the meaning of applicable securities legislation, which reflects the REIT's current expectations regarding future events. Forward‐looking information is based on a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond the REIT's control, that could cause actual results and events to differ materially from those that are disclosed in or implied by such forward‐looking information. Such risks and uncertainties include, but are not limited to, general and local economic and business conditions; the financial condition of tenants; the REIT’s ability to refinance maturing debt; leasing risks, including those associated with the ability to lease vacant space; and interest rate fluctuations. The REIT’s objectives and forward‐looking statements are based on certain assumptions, including that the general economy remains stable, interest rates remain stable, conditions within the real estate market remain consistent, competition for acquisitions remains consistent with the current climate and that the capital markets continue to provide ready access to equity and/or debt. All forward‐looking information in this press release speaks as of the date of this press release. The REIT does not undertake to update any such forward‐looking information whether as a result of new information, future events or otherwise.Additional information about these assumptions and risks and uncertainties is contained in the REIT’s filings with securities regulators.  CONTACT: Contact Information: Investor Relations Nicole Forsythe Tel: 780.945.4707 Tel:1.855.673.6931 (x4707) [email protected]